Page last updated: 2024-11-10

flosequinan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4474062
CHEMBL ID1908307
CHEBI ID134972
SCHEMBL ID122877
MeSH IDM0136718

Synonyms (47)

Synonym
(+-)-7-fluoro-1-methyl-3-(methylsulfinyl)-4(1h)-quinolinone
flosequinanum [latin]
bts 49465
bts-49465
brn 5815383
flosequinan
7-fluoro-1-methyl-3-(methylsulfinyl)-4(1h)-quinolone
4(1h)-quinolinone, 7-fluoro-1-methyl-3-(methylsulfinyl)-
manoplax
flosequinan (usan/inn)
76568-02-0
D04195
CHEBI:134972
AKOS000278656
NCGC00183849-01
bts 49 465
6nb119dlu7 ,
flosequinanum
unii-6nb119dlu7
flosequinan [usan:inn:ban]
7-fluoro-1-methyl-3-methylsulfinylquinolin-4-one
cas-76568-02-0
dtxcid4028759
tox21_113315
dtxsid1048833 ,
CHEMBL1908307
bts-49-465
FT-0630845
154504-94-6
flosequinan [mart.]
flosequinan [mi]
flosequinan [vandf]
7-fluoro-1-methyl-3-methylsulfinyl-4-quinolone
flosequinan [usan]
flosequinan [jan]
flosequinan [who-dd]
flosequinan [inn]
SCHEMBL122877
FE-0065
UYGONJYYUKVHDD-UHFFFAOYSA-N
7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone
7-fluoro-1-methyl-3-(methylsulfinyl)quinolin-4(1h)-one
Q592947
DB13228
(s)-7-fluoro-1-methyl-3-(methylsulfinyl)quinolin-4(1h)-one
7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one
EN300-11686120

Research Excerpts

Overview

Flosequinan (manoplax) is a new vasodilating agent for the treatment of congestive heart failure. It acts by interfering with the inositol-triphosphate/protein kinase C pathway, an important mechanism of vasoconstriction.

ExcerptReferenceRelevance
"Flosequinan (manoplax) is a new vasodilating agent for the treatment of congestive heart failure. "( Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance.
Starling, MR, 1994
)
2.05
"Flosequinan is an arterial and venous vasodilator with actions similar to those of the hydralazine-isosorbide dinitrate combination."( Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Cines, M; Fisher, ML; Gottlieb, SS; Kukin, ML; Medina, N; Packer, M; Penn, J; Taylor, M; Yushak, M, 1993
)
1.29
"Flosequinan is a new vasodilator drug that acts by interfering with the inositol-triphosphate/protein kinase C pathway, an important mechanism of vasoconstriction. "( Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
Creager, MA; Elkayam, U; Massie, BM; Narahara, KA; Packer, M; Pearle, DL; Sullivan, JM, 1993
)
1.97
"Flosequinan is an arterial and venous dilator that also has a positive inotropic effect at relatively higher doses. "( Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium.
Miao, L; Morgan, JP; Perreault, CL; Travers, KE, 1997
)
2
"Flosequinan is a balanced-type vasodilator with a prolonged mode of action due to an approximate 38-hour half-life of its active first metabolite, BTS 53554. "( Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
Bartels, GL; Kruijssen, DA; Look, MP; Remme, WJ, 1995
)
2.01
"Flosequinan is a direct-acting vasodilator that exerts beneficial hemodynamic effects and improves the exercise tolerance of patients with heart failure. "( Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
Arnold, JM; Barr, A; Charbonneau, L; de Champlain, J; Hall, C; Moe, GW; Packer, M; Proulx, G; Rouleau, JL; Sirois, P, 2000
)
1.96
"Flosequinan is a new direct-acting vasodilator that has been shown to be effective in placebo-controlled studies."( A comparison of the effects of captopril and flosequinan in patients with severe heart failure.
Birkhead, J; Cowley, AJ; Hampton, JR; Skene, A; Swami, A; Wynne, RD, 1992
)
1.26
"Flosequinan (BTS 49465) is a putative, selective direct-acting balanced vasodilator currently undergoing evaluation for the treatment of congestive heart failure (CHF) and hypertension. "( Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
Greenberg, S; Touhey, B, 1990
)
1.95
"Flosequinan is an oral arterial and venous vasodilator that is currently under investigation for the treatment of congestive heart failure. "( Flosequinan: a vasodilator with positive inotropic activity.
Corin, WJ; Giustino, S; LeJemtel, T; Monrad, ES; Sonnenblick, ES; Strom, JA, 1991
)
3.17
"Flosequinan is a novel quinolone with cardiovascular activity that is likely to be of value in the treatment of both heart failure and hypertension. "( Pharmacology of flosequinan.
Yates, DB, 1991
)
2.07
"Flosequinan (F) is a potent vasodilator and produces hemodynamic improvement when given to patients (pts) with congestive heart failure (CHF) but little is known about its direct effect on the regional pulmonary vascular bed. "( [Direct vasodilatation effect of flosequinan on pulmonary vascular bed. Estimation by digital perfusion images].
Aizawa, T; Katou, K; Okamoto, K; Tanaka, T, 1991
)
2.01
"Flosequinan is a potentially useful vasodilator for the treatment of hypertension."( Flosequinan as a third agent for the treatment of hypertension: a placebo controlled, double-blind study.
Cowley, AJ; Hampton, JR; Wynne, RD, 1987
)
2.44

Effects

Flosequinan has been shown to improve symptoms and exercise tolerance in patients with heart failure. It has similar long-term efficacy to captopril but is associated with a higher incidence of adverse events.

ExcerptReferenceRelevance
"Flosequinan has similar long-term efficacy to captopril but is associated with a higher incidence of adverse events."( Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril.
Barnett, DB; Bexton, RS; Boyle, R; Cowley, AJ; Hampton, JR; Hanley, SP; McEntegart, DJ; Millar-Craig, M; Morris, GK; Nicholls, AJ, 1994
)
1.23
"Flosequinan has been shown to improve symptoms and exercise tolerance in patients with heart failure. "( Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
Boucher, CA; Burstein, S; Dec, GW; Fifer, MA; Semigran, MJ, 1992
)
1.97
"Flosequinan has the necessary properties of a drug that is likely to be of benefit in the treatment of patients with chronic heart failure."( Clinical efficacy of flosequinan in heart failure.
Cowley, AJ, 1991
)
1.32

Actions

The flosequinan-related increase in exercise duration (+14%) was associated with a significant reduction in VE/VCO2 slope (-16%). The action consistent with a cyclic AMP involvement in the response.

ExcerptReferenceRelevance
"The flosequinan-related increase in exercise duration (+14%) was associated with a significant reduction in VE/VCO2 slope (-16%)."( Flosequinan in chronic heart failure: how is exercise capacity improved?
Banning, AP; Carolan, G; Evans, W; Henderson, AH; Jones, CH; Jones, EA; Ramsey, MW, 1996
)
2.22
"5. Flosequinan was shown to increase calcium inward current in guinea-pig ventricle, an action consistent with a cyclic AMP involvement in the response."( Studies on the cardiac actions of flosequinan in vitro.
Beleta, J; Berga, P; Bou, J; Cardelús, I; Fernández, AG; Gristwood, RW; Llenas, J, 1992
)
1.08

Treatment

Treatment with flosequinan was associated with a decline in median plasma N-ANP levels (2139 pmol/L at baseline to 1625 pmol /L at 1 month)

ExcerptReferenceRelevance
"Flosequinan treatment eliminates this association, highlighting the complexity of the relation between cardiac myocyte damage, drug treatment, and mortality."( Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
Gawad, Y; Hansen, MS; Packer, M; Pitt, B; Rouleau, JL; Stanton, EB; Swedberg, K, 2002
)
1.24
"Treatment with flosequinan was associated with a decline in median plasma N-ANP levels (2139 pmol/L at baseline to 1625 pmol/L at 1 month [P =. "( Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
Arnold, JM; Barr, A; Charbonneau, L; de Champlain, J; Hall, C; Moe, GW; Packer, M; Proulx, G; Rouleau, JL; Sirois, P, 2000
)
0.87

Toxicity

ExcerptReferenceRelevance
" All 10 patients provided analyzable data even though one patient withdrew before the 144-h sample because of an adverse event unrelated to the study medication."( Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction.
Hind, ID; Hinson, JL; Weidler, DJ, 1994
)
0.55
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

The pharmacokinetic and pharmacodynamic effects of co-administration of flosequinan (BTS 49465, CAS 76568-02-0) and digoxin (CAS 20830-75-5) were investigated in 12 healthy volunteers. In the single dose study, the tmax of flOSEquinan was 2.

ExcerptReferenceRelevance
"The pharmacokinetic and haemodynamic effects of a 200 mg oral dose of BTS 49 465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were investigated in a double-blind placebo controlled study."( The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.
Crampton, EL; Hind, ID; Wynne, RD, 1985
)
0.27
"The possible cardiovascular pharmacodynamic interactions at rest and during exercise of combining oral flosequinan (100 mg) with xamoterol (200 mg) was investigated in a four-way randomised double-blind placebo-controlled crossover trial in eight healthy male volunteers."( Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.
Breckenridge, AM; Ng, HW; Tsao, Y; Walley, TJ, 1994
)
0.75
"The pharmacokinetic and pharmacodynamic effects of co-administration of flosequinan (BTS 49465, CAS 76568-02-0) and digoxin (CAS 20830-75-5) were investigated in 12 healthy volunteers."( Effects of concurrent administration of flosequinan and digoxin on the pharmacokinetics of each drug.
Hind, ID; Rau, R; White, SA; Wynne, RD, 1994
)
0.79
" Interpatient variability was appreciable for the plasma and urine concentrations was well as for the calculated pharmacokinetic parameters."( Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction.
Hind, ID; Hinson, JL; Weidler, DJ, 1994
)
0.55
" Elimination rates for 1 decreased by half, and the mean elimination half-life increased to 68."( Pharmacokinetic profile of flosequinan in patients with compromised renal function.
Gallo, BV; Hinson, JL; Weidler, DJ, 1993
)
0.58
"After a single dose of 100 mg, Cmax of the parent compound (2."( Pharmacokinetics of flosequinan in patients with heart failure.
Carson, CA; Droogan, A; Dutka, D; Hind, ID; Johnston, GD; Kendall, M; Morris, GK; Nicholls, DP; Passmore, AP; Taylor, IC; Underwood, LM, 1996
)
0.62
"Phase I trials to study the pharmacokinetic properties of a new drug generally involve a restricted number of healthy volunteers."( Generalized nonlinear models for pharmacokinetic data.
Byrom, WD; Jarvis, P; Jones, B; Lindsey, JK; Wang, J, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Venous blood was taken before and 6 and 24 h after dosing and the serum was analysed for the same solutes as urine."( Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects.
Leary, WP; Reyes, AJ; van der Byl, K; Wynne, RD,
)
0.36
" These results suggest dosage adjustments may be necessary in patients with severe renal dysfunction to prevent excessive accumulation of 1 with repeated dosage of flosequinan."( Pharmacokinetic profile of flosequinan in patients with compromised renal function.
Gallo, BV; Hinson, JL; Weidler, DJ, 1993
)
0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (131)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (13.74)18.7374
1990's94 (71.76)18.2507
2000's7 (5.34)29.6817
2010's6 (4.58)24.3611
2020's6 (4.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.23 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials44 (31.65%)5.53%
Reviews9 (6.47%)6.00%
Case Studies4 (2.88%)4.05%
Observational0 (0.00%)0.25%
Other82 (58.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]